Deutsch English Français

Contact

EP1631235

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1631235

EP1631235 - COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 26.04.2013 Database last updated on 31.08.2024
Most recent event Tooltip	26.04.2013	Application deemed to be withdrawn	published on 29.05.2013 [2013/22]
Applicant(s)	For all designated states Isis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US
	[2011/39]
Former [2006/10]	For all designated states ISIS PHARMACEUTICALS, INC. 1896 Rutherford Road Carlsbad, CA 92008 / US
Inventor(s)	01 / BENNETT, Frank, C. 1347 Cassins Street Carlsbad, CA 92009 / US
	02 / VICKERS, Timothy, A. 253 Luiseno Avenue Oceanside, CA 92057 / US
	03 / KARRAS, James, G. 1159 Montura Road San Marcos, CA 92068 / US
	04 / FREIER, Susan, M. 2946 Renault Street San Diego, CA 92112 / US
	05 / BAKER, Brenda F. 2927 Rancho Cortes Carlsbad CA 92009 / US
	[2006/24]
Former [2006/10]	01 / BENNETT, Frank, C. 1347 Cassins Street Carlsbad, CA 92009 / US
	02 / VICKERS, Timothy, A. 253 Luiseno Avenue Oceanside, CA 92057 / US
	03 / KARRAS, James, G. 1159 Montura Road San Marcos, CA 92068 / US
	04 / FREIER, Susan, M. 2946 Renault Street San Diego, CA 92112 / US
Representative(s)	Hallybone, Huw George, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2008/31]	Hallybone, Huw George, et al Carpmaels & Ransford 43-45 Bloomsbury Square London WC1A 2RA / GB
Former [2008/28]	Hallybone, Huw George Carpmaels & Ransford 43-45 Bloomsbury Square London WC1A 2RA / GB
Former [2006/22]	Manaton, Ross Timothy, et al Bromhead Johnson, Kingsbourne House, 229-231 High Holborn London WC1V 7DP / GB
Former [2006/10]	Hale, Stephen Geoffrey, et al Bromhead Johnson, Kingsbourne House, 229-231 High Holborn London WC1V 7DP / GB
Application number, filing date	04752823.7	19.05.2004
	[2006/10]
	WO2004US15880
Priority number, date	US20030444206	23.05.2003 Original published format: US 444206
	US20030510614P	10.10.2003 Original published format: US 510614 P
	US20030520401P	13.11.2003 Original published format: US 520401 P
	US20040537291P	16.01.2004 Original published format: US 537291 P
	[2006/10]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2005000202
	Date:	06.01.2005
	Language:	EN
	[2005/01]
	Type:	A2 Application without search report
	No.:	EP1631235
	Date:	08.03.2006
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 06.01.2005 takes the place of the publication of the European patent application.
	[2006/10]
Search report(s)	International search report - published on:	US	19.01.2006
	(Supplementary) European search report - dispatched on:	EP	17.04.2008
Classification	IPC:	C12N15/11, A61K48/00, A61P11/06	[2008/20]
	CPC:	C12N15/1138 (EP); A61P11/06 (EP); C12N2310/11 (EP); C12N2310/315 (EP); C12N2310/321 (EP); C12N2310/322 (EP); (+) C12N2310/3341 (EP); Y02P20/582 (EP) (-)
	C-Set:	C12N2310/321, C12N2310/3525 (EP)
	Former IPC [2006/19]	A61K31/70, C12N5/00, C07H21/00
	Former IPC [2006/10]	A61K6/00
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/10]
Extension states	AL	Not yet paid
	HR	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
Title	German:	ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULATION DER EXPRESSION VON B7 PROTEIN	[2006/10]
	English:	COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN	[2006/10]
	French:	COMPOSITIONS ET METHODES DE MODULATION DE L'EXPRESSION DE LA PROTEINE B7	[2006/10]
Entry into regional phase	19.12.2005	National basic fee paid
	19.12.2005	Search fee paid
	19.12.2005	Designation fee(s) paid
	19.12.2005	Examination fee paid
Examination procedure	19.12.2005	Examination requested [2006/10]
	16.07.2008	Amendment by applicant (claims and/or description)
	24.03.2010	Despatch of a communication from the examining division (Time limit: M06)
	23.12.2010	Reply to a communication from the examining division
	01.12.2012	Application deemed to be withdrawn, date of legal effect [2013/22]
	09.01.2013	Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2013/22]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.03.2010
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	23.12.2010	Request for further processing filed
	23.12.2010	Full payment received (date of receipt of payment) Request granted
	14.01.2011	Decision despatched
Fees paid	Renewal fee
	27.03.2006	Renewal fee patent year 03
	07.05.2007	Renewal fee patent year 04
	18.03.2008	Renewal fee patent year 05
	07.05.2009	Renewal fee patent year 06
	31.03.2010	Renewal fee patent year 07
	10.05.2011	Renewal fee patent year 08
	Penalty fee
	Additional fee for renewal fee
	31.05.2012	09 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[PY]WO03083089 (PPL THERAPEUTICS SCOTLAND LTD [GB], et al) [PY] 1-13* figure 1; example 1; claim 1; table 1; compound 1; sequence 1 *;
		[Y] - QIAN S ET AL, "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, (200102), vol. 33, no. 1-2, ISSN 0041-1345, page 551, XP002474973 [Y] 1-13 * the whole document * DOI: http://dx.doi.org/10.1016/S0041-1345(00)02137-0
		[Y] - LIANG X ET AL, "Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, (200102), vol. 33, no. 1-2, ISSN 0041-1345, page 235, XP001036750 [Y] 1-13 * the whole document * DOI: http://dx.doi.org/10.1016/S0041-1345(00)01991-6
		[PY] - LIANG XIAOYAN ET AL, "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", TRANSPLANTATION 27 AUG 2003, (20030827), vol. 76, no. 4, ISSN 0041-1337, pages 721 - 729, XP002474974 [PY] 1-13 * the whole document * DOI: http://dx.doi.org/10.1097/01.TP.0000076470.35404.49
	International search	[X]US6319906 (BENNETT C FRANK [US], et al);
		[X]WO0074687 (ISIS PHARMACEUTICALS INC [US], et al);
		[Y]WO9901579 (ISIS PHARMACEUTICALS INC [US], et al)
	Examination	WO0074687
		US6319906
		WO03083089
		- QIAN S ET AL, "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200102), Database accession no. PREV200100372589
		- LIANG XIAOYAN ET AL, "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (20030827), Database accession no. NLM12973117
		- LIANG X ET AL, "PHENOTYPE AND ALLOSTIMULATORY FUNCTION OF DENDRITIC CELLS TREATED WITH ANTISENSE OLIGODEOXYRIBONUCLEOTIDES TARGETING CD80 OR CD86 MRNA", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, (20010201), vol. 33, no. 1/02, ISSN 0041-1345, page 235, XP001036750 DOI: http://dx.doi.org/10.1016/S0041-1345(00)01991-6

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p